Jabulile Matee

Motivated medical laboratory professional with a strong focus on quality systems maintenance and management, complemented by exceptional documentation and record-keeping skills. A practical problem-solver adopting a proactive approach to addressing systemic errors while continuously enhancing expertise through training and courses. Driven by innovation and creativity, recent leadership in launching a new microbiology laboratory project demonstrated the ability to conduct equipment procurement, outsource consumables, draft management and technical SOPs, and establish standards in alignment with ISO guidelines and SANAS requirements. Committed to fostering excellence and advancing operational efficiency within the laboratory environment.

Tebogo, Mahlahlane,  tebogo.mahlahlane@vpath.co.za, 0724530804, PathCare Vermaak

Bonolo Tladinyane, Sedi.dire@gmail.com  0769094736 , Setshaba Research Center 

• Purpose 1: GS-US-412-5624
• Phase 3, Double-Blinded, Multicenter, Randomized Study to Evaluate Safety and Efficacy of Twice Yearly Long-Acting Subcutaneous Lenacapavir, and Daily Oral Emtricitabine/Tenofovir Alafenamide for Pre- Exposure Prophylaxis in Adolescent Girls and Young Women at Risk of HIV Infection
• IB Alliance: NC-009
• A phase 2, partially-blinded, randomised trial assessing the safety and efficacy of TBA3676 or bedaquiline, in combination with pretomanid and linezolid in adult participants with newly diagnosed, drug-sensitive, smear-positive pulmonary tuberculosis.
• HVTN 605
• A phase 2a clinical trial to evaluate the safety and immunogenicity of MTBVAC in adolescents and adults living with and without HIV in South Africa.
• HVTN 142
• A Phase 1, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Evaluate the Safety, Reactogenicity and Immunogenicity of the HCMV-HIV Vaccine Candidate VIR-1388 in Adult Participants with Overall Good Health and Without HIV
• Pfizer: C3671032
• A Phase 3, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Safety, Tolerability, and Immunogenicity of Respiratory Syncytial Virus (RSV) Perfusion F Subunit Vaccine in Pregnant Participants Living With HIV and Their Infants.
• TB GATES : MRI-TBV02-301
• A Phase 3, randomized, double-blind, placebo-controlled, multicenter, clinical trial to assess the prophylactic efficacy, safety, and immunogenicity of the investigational M72/AS01E-4 Mycobacterium tuberculosis (Mtb) vaccine when Administered intramuscularly on a 0,1-month schedule to adolescents and adults.